INFU logo

InfuSystem Holdings Inc. (INFU)$9.66

Market Cap: 100.46 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for InfuSystem Holdings Inc. (INFU).

HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
DCF ready

Valuation

4.9x

EV/FCF, 20.4% FCF yield

Quality

8.6%

ROIC, 16.6% FCF margin

Growth

8.1%

5Y sales (revenue) CAGR

Balance sheet

0.3x

Debt/equity, 1.8x current ratio

Superinvestors

1

Top: First Eagle Investment Management (0.0%)

Strengths to research

  • Revenue compounded at 8.1% over five years.
  • Free cash flow margin is healthy at 16.6%.
  • Debt/equity looks manageable at 0.3x.
  • 10 annual periods are available for trend analysis.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for INFU.

Grade B
67
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
INFU
Target
InfuSystem Holdings Inc.$100.5M31.2x4.9x8.6%8.1%16.6%56.0%0.7xN/A
COYACoya Therapeutics Inc$107.2M-3.8x-5.6x-49.3%N/A-135.2%N/AN/AN/A
CRBUCaribou Biosciences Inc.$79.9M-1.3x-0.6x-121.2%-2.0%-1006.8%N/AN/AN/A
GUTSFractyl Health Inc$79.8M-0.5x0.0x-1490.3%N/AN/AN/AN/AN/A
CGENCompugen Ltd$128.1M7.4x1.2x34.4%105.2%43.1%87.3%-2.8xN/A
IVVDInvivyd Inc.$69.0M-3.7x2.7x-21.7%N/A-109.1%N/AN/AN/A
DMACDiaMedica Therapeutics Inc.$171.4MN/A-5.4x-58.4%N/AN/AN/AN/AN/A
INBXInhibrx$178.5M-11.2x-0.4x-1752.2%N/A-9986.5%N/AN/AN/A
GANXGain Therapeutics Inc.$56.4M-2.9x-1.9x-106.3%N/AN/AN/AN/AN/A

Financial Charts

No financial data available for INFU (annual).

1 superinvestors own INFU

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
First Eagle Investment Management

First Eagle Investment Management

721,371$7M0.01%0.0%